MIRA INFORM REPORT

 

 

Report No. :

321398

Report Date :

22.05.2015

 

IDENTIFICATION DETAILS

 

Name :

AVERSI-PARMA SHPS

 

 

Registered Office :

Agmashenebeli Street 148/2 Old Tbilisi District  Tbilisi 0112

 

 

Country :

Georgia

 

 

Date of Incorporation :

14.05.1999

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Trading as importers, distributors and wholesalers of pharmaceutical products and diagnostic equipment.

 

 

No. of Employee :

510

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

Lari 5,000,000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Georgia

C1

C1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

GEORGIA ECONOMIC OVERVIEW

 

Georgia's main economic activities include cultivation of agricultural products such as grapes, citrus fruits, and hazelnuts; mining of manganese, copper, and gold; and producing alcoholic and nonalcoholic beverages, metals, machinery, and chemicals in small-scale industries. The country imports nearly all of its needed supplies of natural gas and oil products. It has sizeable hydropower capacity that now provides most of its energy needs. Georgia has overcome the chronic energy shortages and gas supply interruptions of the past by renovating hydropower plants and by increasingly relying on natural gas imports from Azerbaijan instead of from Russia. Construction of the Baku-T'bilisi-Ceyhan oil pipeline, the South Caucasus gas pipeline, and the Kars-Akhalkalaki Railroad are part of a strategy to capitalize on Georgia's strategic location between Europe and Asia and develop its role as a transit point for gas, oil, and other goods. The expansion of the South Caucasus pipeline, as part of the Shah Deniz II Southern Gas Corridor project, will result in a $2 billion foreign investment in Georgia, the largest ever in the country. Gas from Shah Deniz II is expected to begin flowing in 2019. Georgia's economy sustained GDP growth of more than 10% in 2006-07, based on strong inflows of foreign investment and robust government spending. However, GDP growth slowed following the August 2008 conflict with Russia, and sunk to negative 4% in 2009 as foreign direct investment and workers' remittances declined in the wake of the global financial crisis. The economy rebounded in 2010-13, but FDI inflows, the engine of Georgian economic growth prior to the 2008 conflict, have not recovered fully. Unemployment has also remained high. Georgia has historically suffered from a chronic failure to collect tax revenues; however, since 2004 the government has simplified the tax code, improved tax administration, increased tax enforcement, and cracked down on petty corruption, leading to higher revenues. The country is pinning its hopes for renewed growth on a determined effort to continue to liberalize the economy by reducing regulation, taxes, and corruption in order to attract foreign investment, with a focus on hydropower, agriculture, tourism, and textiles production. The government has received high marks from the World Bank for its anti-corruption efforts. Since 2012, the Georgian Dream-led government has continued the previous administration's low-regulation, low-tax, free market policies, while modestly increasing social spending, strengthening anti-trust policy, and amending the labor code to comply with International Labor Standards. The government published its 2020 Economic Development Strategy in early 2014 and former Prime Minister Bidzina IVANISHVILI launched the Georgian Co-Investment Fund, a $6 billion private equity fund that will invest in tourism, agriculture, logistics, energy, infrastructure, and manufacturing. In mid-2014, Georgia signed an association agreement with the European Union, paving the way to free trade and visa-free travel.

 

Source : CIA

 

 

Company name and address

 

AVERSI-PARMA SHPS (CORRECT)

 

AVERSI PHARMA LTD (REQUESTED)

 

 

ADDRESS

 

Street               : Agmashenebeli Street 148/2

 

Area                 : Old Tbilisi District

 

Town                : Tbilisi 0112

Country             : Georgia

 

Telephone         : (995 32) 298 7860 ext. 129 (Chief Accountant) & 253 (Financial Director) / 291 1906 / 299 7970 / 225 0066 ext.115 (Logistics Department) / ext. 104 (Sales Department) / Mobile (995 577) 790 479 (Aleksandr Janashia)

Fax                   : (995 32) 291 1906

E-Mail                : ketino@aversi.ge  / info@aversi.ge

Website            : www.aversi.ge

 

Extended Name  : Aversi-Parma Shazguduli Pasukhismbgeblobis Sazagadoeba

 

English Translation : Aversi - Pharma Ltd

 

 

SENIOR COMPANY PERSONNEL

 

   Name                                                Position

 

1. Irakli Purtseladze                                Managing Director

 

2. Nikoloz Ivliyanovich Kurtanidze           Executive Director

 

3. Aleksandr Janashia                            Financial Director

 

4. Ketino Davidovna Nozadze (Mrs)        Chief Accountant

 

5. Nona Korshvia                                   Assistant to the Managing

                                                                        Director

 

Total Employees :         510 (subject)

                                    4,300 (group)

 

 

PAYMENTS

 

No complaints have been heard regarding payments from local suppliers or banks.

 

Subject is a member of the Aversi Group, the largest pharmaceutical

group in Georgia, operating since 1994. The Group has 35 per cent share of pharmaceutical market of Georgia with its network of drug stores comprising more than 160 pharmacies and 4 medical centres located around Georgia.

 

We consider it is acceptable to deal with subject for LARGE amounts,

although it is normal accepted practice for international suppliers

to deal on secured terms with Georgian importers.

 

Opinion on maximum credit : LARI 5,000,000

 

Trade risk assessment : Normal

 

 

PRINCIPAL BANKERS

 

NAME               : BANK OF GEORGIA

 

Branch              : Pushkin St 3

Town                : Tbilisi 0107

 

Telephone         : (995 32) 997 726

Fax                   : (995 32) 997 726

 

Subject also has account with the following banks:

 

1. TBC-Bank

   Chavchavadze Ave 11

   Tbilisi 380079

   Tel: (995 32) 291 693

   Fax: (995 32) 291 693

 

2. Republic Bank JSC

   Gr. Abashidze Street 2

   Tbilisi 0179

   Telephone: (995 32) 925 555

   Fax      : (995 32) 925 544

 

3. Bazisbank

   Rezo Tabukashvili Street 37

   Tbilisi 0177

   Telephone: (995 32) 298 4736 / 298 9597 / 298 6548

   Fax      : (995 32) 298 6548

 

4. Procredit Bank JSC

   Al. Kazbegi Avenue 21

   Tbilisi 0160 

   Telephone: (995 32) 220 2222

   Fax    : (995 32) 220 2223

 

 

FINANCIAL INFORMATION

 

Private companies in Georgia are not required to publish or disclose balance sheets. However, the subject interviewed offered the following information :

 

Sales Turnover              : LARI 193,000,000 - 2009 - exact

                                                : LARI 204,000,000 - 2010 - exact

                                                : LARI 208,600,000 - 2011 - exact

                                                : LARI 210,000,000 - 2012 – exact

                                     : LARI 212,000,000 - 2013 – exact

                                     : LARI 243,000,000 – 2014 – exact      

 

Net Profit                      : LARI  30,000,000 – 2014 – exact  

 

Total Value of Stock Held : LARI 47,000,000 (as of 1 January 2015)   

 

Financial year ends 31 December.

 

 

LEGAL STATUS AND HISTORY

 

Date Started                 : 14 May 1999

 

History                          : The subject company was established in Georgia on 14 May 1999.

 

C.R. No.                       : 5a/4-2134

 

Tax No.                         : 211386695

 

Authorised Capital         : LARI 2,000

 

Paid-Up Capital             : LARI 2,000

 

Shazguduli Pasukhismbgeblobis Sazagadoeba (limited liability company) with the following director and shareholders :

 

Director

 

Irakli Purtseladze

(Georgian national / Personal No.: 01026002800)

 

Shareholders                                                               Percentage

                                                                                   

1. Paata Nikolayevich Kurtanidze                                                67%

   (Georgian national / Personal No.: 01024002260)

 

2. Nikoloz Ivliyanovich Kurtanidze                                   33%

   (Georgian national / Personal No.: 60003003778)

 

Affiliated companies of Aversi-Pharma ShPS :

 

Associates

 

1. Aversi - Geofarm ShPS

   Kostava Street 11 

   Dzveli District

   Tbilisi

   Managing Director: Gia Chigogidze

   Est.: 18 August 1995

   C.R. No.: 4/4-67

   ID Code : 203834075 

   Shareholders:

            - Paata Kurtanidze   67%

            - Nikoloz Kurtanidze 33%

  (Retail of pharmaceutical products)

 

2. Aversi - Ratsional ShPS

   Chirkhnauli Street 14

   Tbilisi 0198

   Managing Director: Malkhaz Kurtanidze

   Est.: 11 January 2002

   C.R. No.: 7/4-1961

   ID Code : 208216107

   Shareholders:

              - Paata Kurtanidze   60%

              - Nikoloz Kurtanidze 25%

              - Malkhaz Kurtanidze 15%    

  (Manufacturer of pharmaceuticals)

 

3. Aversi Klinik ShPS

   V. Pshavela Avenue 27B

   Tbilisi

   Est. 2009

  (Operator of a medical centre)

 

4. Alfa ShPS

   Bagrationi Street 6

   Tbilisi

   Est.: 2010

 

Subject’s former affiliate :

 

Aversi ShPS

(address as per heading)

Tax Code : 211752263

Statistics Code : OKPO 20340175

 

 

ACTIVITIES

 

The Company is involved in the following activities :

 

Trading as importers, distributors and wholesalers of pharmaceutical products and diagnostic equipment.

 

NACE Code: 4646

 

Imports from Lithuania, Latvia, Estonia, Russia, Ukraine, Belarus,

Germany, UK, Bulgaria, Hungary, Poland, France, Belgium, Italy,

Switzerland, Serbia, Iceland, Finland, Turkey, Israel, India and USA.

 

Exports to Armenia and Azerbaijan.

Overseas suppliers include:

 

Actavis International (Iceland)

Ahava (Israel)

Asfarma (Turkey)

Astellas Pharma (Japan-Netherlands)

Bayer Schering Pharma (Germany)

Berlin-Chemie (Germany)

Biocodex (France)

Boehringer Ingelheim (Germany)

Rup Borisovskiy Zavod (Belarus)

Borshagovsk Chem. Pharm. Plant (Ukraine)

Brupharmexport (Belgium)

Chephasaar (Germany)

Darnitsa (Ukraine)

Dr. Theiss Naturwaren GmbH (Germany)

Fresenius kabi Deutschland GmbH (Germany)

Farmila - Thea Farmaceutical Spa (Italy)

F. TRENKA (Austria)

Georg Biosystem (Ukraine)

GlaxoSmithKline (UK)

Grindex (Latvia)

Hemofarm (Serbia)

Hemoplast (Ukraine)

Herbapol (Poland)

Intas (India)

Italfarmaco (Italy)

Jugoremedia (Serbia)

Kievmedpreparat (Ukraine)

Kiev Vitamin Factory (Ukraine)

Krasfarma (Russia)

Lisapharma (Italy)

Liqvor (Armenia)

Microlife (Switzerland)

Naturprodukt (Poland)

Nizhpharm (Russia)

Nycomed (Austria)

Olainfarm (Latvia)

Pfizer (USA-Belgium)

Phitopharm (Ukraine)

Polpharma S.A. (Poland)

Rottapharm (Italy)

Rusan Pharma (India)

Sanofi Aventis (France)

Santen OY (Finland)

Solvey Pharmaceutical (Switzerland)

Tonus-Elast (Latvia)

Yuriya Pharm (Ukraine)

Zdorovie (Ukraine)

Ziololek (Poland)

 

 

FACILITIES

 

The Company has the following facilities :

 

Owned premises comprising administrative offices, a wholesale outlet, one pharmacy and warehousing facilities located at the heading address as well as another 3 warehouses located at Vazha-Pshavela Avenue 27B (Tbilisi), Tsinakhuli Street 14 (Tbilisi) and Kazbegi Street 16 (Tbilisi).

 

 

REGISTERED OFFICE

 

Agmashenebeli Street 148/2

Old Tbilisi District

Tbilisi 0112

 

 

SPECIAL NOTE

 

You enquired on : AVERSI PHARMA LTD. Please note that subject’s correct registered name is as per heading.

 

Interviewed : Ketino Davidovna Nozadze (Mrs) (Chief Accountant).

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.70

UK Pound

1

Rs.98.92

Euro

1

Rs.70.67

 

 

INFORMATION DETAILS

 

Analysis Done by :

RAS

 

 

Report Prepared by :

ANK

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.